Healthcare | November 18, 2022
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
